Our clinical experience, pilot testing and some examples of holoimaging

 

The BHT-technology is already being used in everyday practice by our collaborators from several countries – mostly private medical doctors. We do not disclose the BHT-results  to patients – only their medical doctors are provided with information on benign/malignant nature of pathological processes, their aggressiveness and approximate location within the body. The communication with medical professionals from various countries is usually conducted via network. 

Up to 13800 persons have been tested since 2000 in order to study the holographic manifestation of  various pathological states. The presently used (automatable) version of the cancer-detecting BHT-technology has been developed in 2008.

The first "blind" trial of BHT  (an early version of the device)

The first clinical study took place in 2007 at the P. A. Hertzen Research Institute of Oncology in Moscow (Russia) in collaboration with the Center of Bioholography (Tbilisi, Georgia) and the International Association of Bioholography (AIPEB, Nice, France). An older, non-automatable version of the BHT has been tested.

Encoded BHT-grams of patient fingertips were transferred to Georgian analysts via network with indication of gender and age of the study participants. Clinical diagnoses of patients were disclosed only upon the end of the trial. The BHT-diagnoses of 30 cases out of 35 coincided with information provided later by oncologists (two were false-positive and three false-negative results). However, in two cases of early-stage cancer the BHT-results turned out to be more accurate than X-ray and ultrasound imaging: these patients have been considered as free of cancer and were included into the control group. Only microscopic evaluation of tissue specimens prompted by cancer-positive BHT-results, revealed early-stage malignant processes, namely the stage 1 thyroid cancer and an early-stage carcinoma of breast (Table 1). This small-scale clinical trial clearly showed the ability of the tested technology to detect malignant tumors in humans with accuracy no less than 85%. Results of this study have been published with co-authorship of Russian oncologists [Shaduri, et al., (2008). Proceedings of the Int. conf. „Actual problems of modern physics“,  pp. 94-97]. 

Some other testimonials

At each step of R&D we were testing new versions of the devices within the framework of private collaboration with various medical professionals.  For example, 11 persons have been examined at the Department of Gastroenterology at the Centre Hospitalier St. Philibert in Lille, France with 2 blinded tests later confirmed by clinicians. Professor Bernard Filoche - the former head of this department writes the following: “It is always difficult to appreciate the value of innovative modalities that are at the forefront of medical physics and conventional medicine. However, results obtained in the pilot study prove the efficiency of the CID- system” [doc 1].

Collaboration with radiologists from the Hospital in Cannes (France) also demonstrated total coincidence of BHT and clinical results regarding cancer and metastasis presence [doc 2], whereas in New Zealand the efficiency of BHT was proved while monitoring several patients with multiple sclerosis [doc 3]. 

Cancer early detection: several examples

There are numerous cases where the CID-test revealed the BHT-signatures of aggressively growing malignant tumors several months earlier than conventional imaging technologies. An example of an early diagnosis of leucosis is presented below.

Three BHT-grams of the patient with initially benign dismyelopoiesis (left thumb) shown on figure 1, demonstrate a BHT-manifestation of early carcinogenesis. The first BHT-signatures of cancer have been detected in March 2007 (frame #1) though blood tests failed to confirm our data. Significant aggravation of the disease in June 2007 (frame #2) has not been confirmed by onco-hematologists either. In September 2007 the patient was hospitalized due to acute leucosis and liver metastasis. The BHT-gram #3 was recorded during the course of chemotherapy. 

The presented case illustrates high sensitivity of body's spectra to early-stage cancers. Please note that pathological processes in blood-cells provide holograms with a huge resolution - proliferating leukocytes are best displayed in the lower part of frame 2. Dr. Marc Bouchoucha from Nice, France talks about the case (video)

There are many similar cases of the malignancy detection or exclusion prior to clinical manifestation or confirmation by conventional methods of diagnostics. Sometimes the BHT-conclusions rule out the cancer-diagnosis of radiologists (e.g., see BHT-results of Tobel  & Michael_W).  

Several examples of the holographic imaging of various types of cancer (on fingertip BHT-grams) are shown below - see figures 2-5.          

Emission of an adequately prepared healthy person's fingertips is evenly distributed around contact surface showing no signs of major gradients of brightness or geometrical artifacts; any significant violation of homeostasis in any part of human body, especially when caused by malignant pathology, alters normal texture and shapes of fingertip coronas. Distorted and zoomed areas display the holographic replicas of the most troubled organs, tissues and/or cells.

It is possible to monitor the disease by its expression on fingertip BHT-grams. Many patients of collaborating medical professionals are followed up for years.The CID-system provides complementary information that alerts doctors in cases of the disease aggravation and also enables them to evaluate the efficiency of this or that treatment (an example is shown on fig. 3).

 

Metastatic lesions are usually displayed with huge resolution (figures 4 and 5).

 

 

 

 

 

 

 

 

 

 

 

 

 

---

Back to Home >>>